Related Experiment Video
Updated: Oct 8, 2025
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids
Silvia Pascual-Sabater1, Giulia Raimondi1, Ana Mato-Berciano1
1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya 08036, Spain.
Abstract:
Patient-derived organoids (PDOs) have shown the potential to reflect patient sensitivity to chemotherapeutic or targeted drugs. Recently, we showed that organoid models can also serve as a platform to screen for selectivity and potency of oncolytic adenoviruses (OAds). In this protocol, we describe the steps for tumor organoid adenoviral infection and functional assessment of patient-specific responses to OAds. We provide methods to determine OAd relative efficacy by evaluation of PDO viability after infection and adenoviral replication within cancer cells. For complete details on the use and execution of this protocol, please refer to Raimondi et al. (2020).
Insights
Patient-derived organoids (PDOs) can predict responses to oncolytic adenoviruses (OAds). This protocol details how to infect tumor organoids and assess patient-specific OAd efficacy, evaluating cancer cell viability and viral replication.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Patient-derived organoids (PDOs) accurately model patient drug sensitivity.
- Organoid models are emerging as platforms for screening oncolytic viruses.
- Oncolytic adenoviruses (OAds) show promise as cancer therapeutics.
Purpose of the Study:
- To provide a protocol for infecting tumor organoids with OAds.
- To establish methods for assessing patient-specific responses to OAds.
- To determine the relative efficacy of OAds in preclinical models.
Main Methods:
- Infection of PDOs with OAds.
- Assessment of PDO viability post-infection.
- Quantification of adenoviral replication within cancer cells.
Main Results:
- The protocol enables functional assessment of patient-specific OAd responses.
- Methods allow for evaluation of OAd relative efficacy.
- PDOs serve as a viable platform for OAd screening.
Conclusions:
- This protocol facilitates the preclinical evaluation of OAds using patient-derived organoids.
- The methods described can guide the development of personalized oncolytic virotherapy.
- PDOs offer a valuable tool for assessing OAd selectivity and potency.
